Acne Vulgaris Market Summary
In 2023, the US led the Acne Vulgaris market across the 7MM, valued at about USD 2,949 million, with growth projected through 2034. The 7MM reported nearly 29.4 million diagnosed cases, expected to rise due to factors like hormones, diet, genetics, and pollution. The highest prevalence was seen in the 15–19 age group, with around 5.9 million cases in the US. Emerging therapy SB204, anticipated to launch in 2027, is expected to significantly ease the acne burden in coming years.
DelveInsight’s report, “Acne Vulgaris Market Insights, Epidemiology, and Market Forecast – 2034” provides a comprehensive overview of Acne Vulgaris, including historical and projected epidemiology as well as therapeutic market trends across the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan. The report presents detailed insights into revenue patterns, disease prevalence, and the treatment landscape, while also analyzing the market size and growth potential. It further explores the pipeline of emerging therapies, their clinical progress, and the impact of ongoing and upcoming trials expected to shape future treatment strategies. This study serves as a valuable resource for understanding market dynamics and the evolving therapeutic opportunities in Acne Vulgaris.
Unlock key insights into the Acne Vulgaris Market! Download DelveInsight’s comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Acne Vulgaris Market Size
Key Takeaways from the Acne Vulgaris Market Report
- The Acne Vulgaris market size was valued ~USD 4,256 million in 2023 among the 7MM countries and is anticipated to grow with a significant CAGR during the study period (2020-2034)
- In May 2025, AOB Pharma reported new metabolomic insights on B244, showing it produces multiple skin-beneficial metabolites, with select data presented at the Dermatology Drug Development Summit Europe, highlighting its potential for broader therapeutic applications.
- In April 2025, Dermata reported Phase III results showing XYNGARI achieved significant efficacy, separating from placebo after four weekly treatments, positioning it as a potential first once-weekly topical for moderate-to-severe acne.
- In April 2025, Cosmo reported that the EMA’s CHMP issued a negative opinion on WINLEVI’S marketing application in Europe, citing concerns over its benefit-risk profile in adolescents. The company plans to request a re-examination, emphasizing positive trial results, safety data, and real-world evidence supporting its use in both adolescents and adults.
- In March 2025, Dermata Therapeutics, Inc. (Nasdaq: DRMA, DRMAW), a late-stage biotechnology company specializing in medical and aesthetic skin disease treatments, has announced the completion of the final patient visit in its pivotal Phase 3 Spongilla Treatment for Acne Research (STAR-1) trial. The trial is evaluating XYNGARITM, a novel once-weekly topical treatment designed for moderate-to-severe acne
- In March 2025, Kane Biotech Inc. (TSX-V: KNE, OTCQB: KNBIF) has received approval from the Internal Review Board (IRB) of the University of Miami Health System (UHealth) to initiate a clinical study evaluating its DispersinB® Acne Cleanser prototype for treating mild to moderate Acne Vulgaris.
- In March 2025, Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company focused on developing therapies for metabolic and fibrotic diseases, has received FDA clearance for its Investigational New Drug (IND) application for TVB-3567, the company's second fatty acid synthase (FASN) inhibitor. This potent and selective small molecule is set to enter clinical development for acne treatment. The IND approval from the FDA's Division of Dermatology and Dentistry paves the way for a first-in-human Phase 1 trial of TVB-3567, expected to begin in 2025.
- In February 2025, Glenmark received MHRA approval to market WINLEVI in the UK for patients aged 12 and older, under its licensing agreement with Cosmo Pharmaceuticals for European distribution. In August 2020, the US FDA approved WINLEVI (clascoterone) for the topical treatment of acne vulgaris in patients 12 years of age and older.
- In 2023, the US had the largest market size for Acne Vulgaris among the 7MM, reaching approximately USD 2,949 million, with expectations for further growth by 2034.
- Among European countries, Germany had the largest Acne Vulgaris Market Size in 2023, reaching USD 311 million, while the UK had the smallest market size, with USD 121 million.
- In 2023, the Acne Vulgaris Market Size in Japan was approximately USD 316 million, with expectations for continued growth by 2034.
- In 2023, the 7MM reported around 29,433 thousand diagnosed prevalent cases of Acne Vulgaris, with an anticipated rise in cases throughout the forecast period from 2024 to 2034.
- In 2023, the 7MM saw an estimated ~140,217 thousand cases of Acne Vulgaris, with the US accounting for around 69,500 thousand cases. These figures are expected to grow consistently over the forecast period.
- The prevalence of Acne Vulgaris is categorized by age groups: 15-19 years, 20-29 years, 30-39 years, 40-49 years, and 50 years and older. In the United States, the highest number of cases was seen in the 15-19 age group, with approximately 5,853 thousand cases reported in 2023.
- The upcoming drug SB204 is anticipated to enter the US market by 2027, with the potential to alleviate the burden of acne vulgaris during the forecast period.
- Key Acne Vulgaris Companies: BioPharmX, Bausch Health Americas, Inc., Kintor Pharma, Sol-Gel Technologies, Ltd., Ascletis Pharma, Galderma R&D, Torrent Pharma, Dermata Therapeutics, Clinuvel Pharma, Novan, Inc., Dermata Therapeutics, Accelovance, Balmoral Medical, Vyne Therapeutics Inc., XOMA (US) LLC, Braintree Laboratories, Teva Pharma, AnaptysBio, Inc., Janssen Research, Cutia Therapeutics, Bausch Health, and others
- Key Acne Vulgaris Therapies: BPX-01, IDP-120, GT20029, KX-826, S6G5T-3, ASC40, GK530G, Dapsone, DMT310, CD5789 (trifarotene), Afamelanotide, NVN1000, Hydrogen Peroxide, Trifarotene Cream, S6G5T-3, GDC 268 Lotion, Isotretinoin, gevokizumab, BLI1100, AKLIEF®, Imsidolimab, RA-18C3, FMX101, IDP-126, and others
- The Acne Vulgaris epidemiology based on gender analyzed that females are predominantly affected compared to males
- The Acne Vulgaris market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Acne Vulgaris pipeline products will significantly revolutionize the Acne Vulgaris market dynamics.
Stay ahead in the competitive landscape of the Acne Vulgaris Market. Access DelveInsight’s in-depth market analysis and strategic insights today! Click here for more @ Acne Vulgaris Treatment Market Size
Acne Vulgaris Epidemiology
In 2023, there were ~140.2 million Acne Vulgaris prevalent cases across the 7MM, with the US contributing ~69.5 million. Females accounted for 63% of diagnosed cases, showing higher prevalence than males. By severity, moderate cases dominated (45%), while severe cases were least common (10%). Acne Vulgaris prevalence is expected to rise during the forecast period.
Acne Vulgaris Epidemiology Segmentation in the 7MM
- Acne Vulgaris Prevalent Cases
- Acne Vulgaris Diagnosed Prevalent Cases
- Acne Vulgaris Severity-specific Diagnosed Prevalent Cases
- Acne Vulgaris Gender-specific Diagnosed Prevalent Cases
- Acne Vulgaris Age-specific Diagnosed Prevalent Cases
Download the report to understand which factors are driving Acne Vulgaris epidemiology trends @ Acne Vulgaris Prevalence
Acne Vulgaris Marketed Drugs
- AKLIEF (Trifarotene)/ CD-5789: Galderma S.A.
Trifarotene, a first-in-class fourth-generation topical retinoid, has been approved by the FDA for the treatment of acne vulgaris in patients aged 9 years and older. This novel retinoid selectively targets retinoic acid receptor gamma (RAR?), the most common RAR found in the skin, making it a more targeted and skin-specific treatment compared to earlier-generation retinoids. Trifarotene is effective in reducing inflammatory lesions on the face and trunk, with significant improvements observed as early as 2 weeks on the face and 4 weeks on the back, shoulders, and chest. The cream is well tolerated, with common adverse reactions including application-site irritation, pruritus, and sunburn.
- AMZEEQ (minocycline): Journey Medical Corporation/Vyne Therapeutics Inc.
In 2019, the FDA approved AMZEEQ, a foam formulation of the tetracycline antibiotic minocycline, for treating severe acne in adults and children aged 9 years and older. AMZEEQ is specifically indicated for treating pimples and red bumps (non-nodular inflammatory lesions) linked to moderate to severe acne. This new formulation utilizes Foamix's proprietary Molecule Stabilizing Technology (MST) platform to deliver minocycline in a foam form, offering a more targeted and effective treatment option. Furthermore, minocycline is also approved by the FDA for treating rosacea in adult patients, expanding its therapeutic applications in dermatology.
- ARAZLO (tazarotene): Bausch Health Companies Inc. / Ortho Dermatologics
ARAZLO, a topical cream containing tazarotene as the active ingredient, is a treatment option for acne vulgaris in patients aged 9 years and older. The cream combines tazarotene with three moisturizers: sebacic acid, light mineral oil, and sorbitol, allowing it to be highly effective against acne while minimizing skin irritation. Additionally, ARAZLO lotion employs patented polymeric emulsion technology, which enhances skin absorption and reduces irritation, making it a comprehensive treatment option for acne patients.
Acne Vulgaris Emerging Drugs
SB204 (Pelthos Therapeutics)
A topical nitric oxide-releasing monotherapy targeting inflammation and bacterial colonization, offering anti-inflammatory and antibacterial benefits for acne vulgaris. B244 (AOBiome LLC)
A topical microbiome-restoring therapy using Nitrosomonas eutropha to produce antibacterial nitrite and anti-inflammatory nitric oxide, reducing cytokines linked to atopic responses. DMT310 (Dermata Therapeutics)
A Spongilla-based therapy targeting IL-17A/17F, currently in Phase III trials, with potential for both medical and cosmetic acne treatment.
Discover the future of Acne Vulgaris Treatments with DelveInsight's latest market report. Get expert insights and forecasts—download now! @ Acne Vulgaris Market Drivers and Barriers
Acne Vulgaris Market Outlook
In 2023, the Acne Vulgaris Market Size in the 7MM was ~USD 4,256 million, projected to grow through 2034. The market is driven by rising prevalence, skincare awareness, and demand for new therapies. Current options include topicals (salicylic acid, azelaic acid), systemics (oral antibiotics, isotretinoin, hormonal agents), but remain insufficient, highlighting the need for novel treatments. Emerging drugs like SB204, DMT310, B244, BPX-01, and BTX-1503 show promise. Regionally, Germany led Europe (USD 311M), while the UK had the lowest (USD 121M); Japan’s market was USD 316M, expected to grow further.
Acne Vulgaris Market Drivers
- Rising prevalence of acne, especially in adolescents and young adults.
- Growing skincare awareness and demand for dermatological treatments.
- Advancements in topical & systemic therapies improving patient outcomes.
- Pipeline innovation with novel drugs (e.g., SB204, DMT310, B244, BPX-01, BTX-1503).
- Lifestyle factors (diet, pollution, hormonal changes) fueling diagnosis rates.
Acne Vulgaris Market Barriers
- Limited efficacy and safety concerns with existing therapies (e.g., isotretinoin side effects).
- High relapse rates after discontinuation of treatment.
- Antibiotic resistance reducing effectiveness of long-term antibiotic use.
- Cosmetic stigma & underreporting—not all patients seek medical care.
- High treatment costs and limited insurance coverage in some regions.
Scope of the Acne Vulgaris Market Report
- Coverage- 7MM
- Study Period- 2020-2034
- Acne Vulgaris Companies- Galderma Labs, Ortho Dermatologics, Bausch Health, Timber Pharmaceuticals, BioPharmX, Botanix Pharmaceuticals, Kintor Pharma, and others.
- Acne Vulgaris Therapies- B244, SB204, DMT310, BTX 1503, and others.
- Acne Vulgaris Therapeutic Assessment: Acne Vulgaris Current Marketed and Acne Vulgaris Emerging Therapies
- Acne Vulgaris Market Dynamics: Acne Vulgaris market drivers and Acne Vulgaris market barriers
- Acne Vulgaris Unmet Needs, KOL’s views, Analyst’s views, Acne Vulgaris Market Access and Reimbursement
Explore the dynamics of the Acne Vulgaris Market with DelveInsight. From market size to emerging drugs—find it all in our latest report. Read now! @ Acne Vulgaris Ongoing Clinical Trials Analysis
Table of Content
1 Key Insights
2 Report Introduction
3 Acne Vulgaris Epidemiology Overview at a Glance
4 Epidemiology Forecast Methodology
5 Executive Summary
6 Key Events
7 Disease Background and Overview
8 Epidemiology and Patient Population
9 Patient Journey
10 KOL Views
11 Appendix
12 DelveInsight Capabilities
13 Disclaimer
14 About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services